RxDoctor Payments Data

Boo Ghee Low, MD

Hematology & Oncology · Phoenix, AZNPI 1629024955

Payments from drug & device makers

$25,267in general payments, 2019–2025

Across 1,168 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$2K
  • Genentech USA, Inc.$1K
  • Johnson & Johnson$1K
  • Merck$1K
  • Pfizer$1K
  • plus $15K from 54 others

What the payments were for

  • Food & beverage$23,18992%
  • Education$1,3465%
  • Other$7323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis107$2,440
AstraZeneca(2 entities)100$2,313
Genentech USA, Inc.61$1,363
Johnson & Johnson(2 entities)64$1,361
Merck56$1,229
Pfizer70$1,083
Amgen40$1,083
E.r. Squibb & Sons, L.L.C.59$1,016
Seagen Inc.42$1,012
Astellas Pharma US Inc27$876
Lilly USA, LLC32$873
Sanofi39$807
Bristol Myers Squibb54$736
Daiichi Sankyo Inc.25$614
AbbVie28$528
Bayer31$518
GSK19$396
EMD Serono, Inc.19$345
Ipsen Biopharmaceuticals, Inc17$338
Sumitomo Pharma America, Inc.3$337
Pharmacyclics LLC, An Abbvie Company16$336
Eisai Inc.15$329
Takeda Pharmaceuticals U.S.A., Inc.13$291
Gilead(2 entities)15$290
Incyte Corporation15$280
Regeneron Healthcare Solutions, Inc.10$279
Sobi, Inc11$250
Array Biopharma Inc15$242
Puma Biotechnology, Inc.11$214
Adaptive Biotechnologies Corporation5$214
Blueprint Medicines Corporation11$212
Exelixis Inc.8$208
Kyowa Kirin, Inc.9$183
Rigel Pharmaceuticals, Inc.8$165
Clovis Oncology, Inc.10$161
Jazz Pharmaceuticals Inc.8$161
Sun Pharmaceutical Industries Inc.7$147
Caris MPI, Inc.1$140
ADC Therapeutics America, Inc.6$131
Tersera Therapeutics LLC4$123
AVEO Pharmaceuticals, Inc.5$113
Boehringer Ingelheim5$110
CTI Biopharma Corp.4$108
Taiho Oncology, Inc.4$93
Sanofi-aventis U.S. LLC1$85
Beigene USA, Inc.4$83
Karyopharm Therapeutics Inc.3$73
Coherus Oncology, Inc.3$71
Servier Pharmaceuticals LLC3$69
Agios Pharmaceuticals, Inc.3$61
Mylan Institutional Inc.3$57
Morphosys, US Inc.3$57
Verastem, Inc.4$54
Genmab U.S., Inc.2$53
Macrogenics, Inc.2$53
Mirati Therapeutics, Inc.3$50
Global Blood Therapeutics, Inc.3$49
Aurobindo Pharma USA, Inc.3$44
Dendreon Pharmaceuticals LLC2$42
Pharmaessentia USA Corporation2$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,267 in reported general payments places this provider in the 45th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,365,938
Medicare patients
390
Services billed
105,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib15$276,944
BrukinsaZanubrutinib13$205,502
TasignaNilotinib Hcl14$134,570
EliquisApixaban20$24,740
XareltoRivaroxaban15$22,042
Dexamethasone17$419
Hydroxyurea14$388
Letrozole12$388
Anastrozole12$372
Ondansetron OdtOndansetron16$355
Tamoxifen Citrate11$258
Olanzapine11$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$336$276,94415 claims
Beigene USA, Inc.Brukinsa$83$205,50213 claims
NovartisTasigna$2,440$134,57014 claims
PfizerEliquis$1,083$24,74020 claims
Johnson & JohnsonXarelto$1,361$22,04215 claims
Lilly USA, LLCOlanzapine$873$11711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →